^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3023 Lenalidomide As Maintenance Therapy after R-CHOP Has No Protecting Effect for Central Nervous System Relapse in Frontline Treatment of Diffuse Large B-Cells Lymphoma. an Ancillary Studies of the Remarc Study
Published date:
11/04/2020
Excerpt:
Median age was 68 (58-80), 392 pts (63%) had elevated LDH, 575 pts (89%) presented disseminated disease...We retrospectively classified patients into groups of low- (n= 30, 5%), intermediate- (n= 377, 61%), and high-risk (n=215, 35%) CNS-IPI. MYC, MYC/BCL2, MYC/BCL2/BCL6 rearrangements were present in 10, 5 and 1 pts respectively. MYC expression alone, double expressor (DEL) (MYC/BLC2) were present in 79 pts (40%) and 71 pts (34%), respectively.
Trial ID:
Source:
Title:
MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge
Published date:
04/01/2021
Excerpt:
A fluorescence in situ hybridization (FISH) showed MYC and BCL2 rearrangements. Finally a leukemic DLBCL was diagnosed and immediately treatment with rituximab cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) was started. Due to MYC-positivity, lenalidomide was added to the therapy regimen. After treatment the patient achieved complete remission without any clinical sequelae, which is still ongoing after 4 years.
Secondary therapy:
R-CHOP
DOI:
https://doi.org/10.14740/jh818
